Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
GT-201 by Shanghai Grit Biotechnology for Non-Small Cell Lung Cancer: Likelihood of Approval
GT-201 is under clinical development by Shanghai Grit Biotechnology and currently in Phase II for Non-Small Cell Lung Cancer. According...
Data Insights
GT-201 by Shanghai Grit Biotechnology for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
GT-201 is under clinical development by Shanghai Grit Biotechnology and currently in Phase II for Recurrent Head And Neck Squamous...